gastroenterology
IBD

Biosimilars in Australia: Where are we now?

Sponsored by Pfizer Australia Pty Ltd

The introduction of biosimilars into Australia was met with debate on whether the cost savings to the healthcare system would be at the expense of patient safety1. Since then, clinicians have gained more experience with their use and the clinical evidence has grown, providing a better understanding of the efficacy and safety of these agents. ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic